Published in Antimicrob Agents Chemother on May 01, 1987
Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother (2010) 0.88
Reversing the myths obstructing the determination of optimal age- and disease-based drug dosing in pediatrics. J Pediatr Pharmacol Ther (2011) 0.77
Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period. AMA J Dis Child (1958) 9.70
Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome. J Pediatr (1985) 4.26
Pseudomonas cepacia: biology, mechanisms of virulence, epidemiology. J Pediatr (1986) 2.38
Occurrence and antimicrobial susceptibility of gram-negative nonfermentative bacilli in cystic fibrosis patients. Diagn Microbiol Infect Dis (1985) 1.61
Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. J Infect Dis (1983) 1.32
Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis. Pediatr Infect Dis (1985) 1.19
Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study. J Pediatr (1984) 1.16
Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response. J Antimicrob Chemother (1983) 1.12
Pharmacokinetics of methicillin in patients with cystic fibrosis. J Infect Dis (1977) 1.10
Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis. J Pediatr (1984) 1.04
Ceftazidime disposition in acute and stable cystic fibrosis. Clin Pharmacol Ther (1984) 1.03
Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis. J Pediatr (1983) 1.00
Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis. Pediatr Infect Dis (1983) 0.97
Comparison of cefpiramide (HR-810) and four anti-pseudomonal beta-lactam agents against pseudomonas isolates from children with cystic fibrosis. J Antimicrob Chemother (1985) 0.92
Ceftazidime therapy in patients with cystic fibrosis and multiply-drug-resistant pseudomonas. Am J Med (1985) 0.90
Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell (2001) 4.78
Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet (1990) 4.39
Pseudomonas cepacia colonization among patients with cystic fibrosis. A new opportunist. Am Rev Respir Dis (1985) 3.71
Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science (2002) 3.46
Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology (2005) 3.42
Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. Hum Mol Genet (1993) 3.17
Multiple of isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis. J Infect Dis (1979) 3.02
Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis. Risk factors and outcomes. Chest (1987) 2.97
Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis (1983) 2.41
Pneumothorax in cystic fibrosis: a 26-year experience. Ann Thorac Surg (1989) 2.23
The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol (2001) 2.18
Preparation and measurement of three-qubit entanglement in a superconducting circuit. Nature (2010) 2.15
Pseudomonas cepacia: decrease in colonization in patients with cystic fibrosis. Am Rev Respir Dis (1986) 2.10
Enzyme replacement therapy for adenosine deaminase deficiency and severe combined immunodeficiency. N Engl J Med (1976) 2.04
Biochemical and pathologic evidence for proteolytic destruction of lung connective tissue in cystic fibrosis. Am Rev Respir Dis (1985) 2.04
Essential requirement of BMPs-2/4 for both osteoblast and osteoclast formation in murine bone marrow cultures from adult mice: antagonism by noggin. J Bone Miner Res (2000) 2.03
Course of cystic fibrosis in 95 patients. J Pediatr (1976) 1.78
Cross-sectional and longitudinal studies of naturally occurring antibodies to Pseudomonas aeruginosa in cystic fibrosis indicate absence of antibody-mediated protection and decline in opsonic quality after infection. J Infect Dis (1995) 1.63
Efficacy of the Flutter device for airway mucus clearance in patients with cystic fibrosis. J Pediatr (1994) 1.61
Assessing distress in pediatric intensive care environments: the COMFORT scale. J Pediatr Psychol (1992) 1.56
The effect of early diagnosis and treatment in cystic fibrosis: a seven-year study of 16 sibling pairs. Am J Dis Child (1977) 1.55
Restoration of in-vitro lymphocyte responses with exogenous adenosine deaminase in a patient with severe combined immunodeficiency. Lancet (1975) 1.50
Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology (2006) 1.49
Acetaminophen-associated hepatic injury: evaluation of acetaminophen protein adducts in children and adolescents with acetaminophen overdose. Clin Pharmacol Ther (2008) 1.48
Cultures of thoracotomy specimens confirm usefulness of sputum cultures in cystic fibrosis. J Pediatr (1984) 1.47
Lymphocyte responsiveness to Pseudomonas aeruginosa in cystic fibrosis: Relationship to status of pulmonary disease in sibling pairs. J Pediatr (1978) 1.45
Mechanical ventilators optimized for pediatric use decrease work of breathing and oxygen consumption during pressure-support ventilation. Crit Care Med (1994) 1.44
Cardiac toxicity associated with intravenous erythromycin lactobionate: two case reports and a review of the literature. Pediatr Infect Dis J (1993) 1.43
Continuous propofol infusion for the relief of treatment-resistant discomfort in a terminally ill pediatric patient with cancer. J Pediatr Hematol Oncol (1996) 1.42
Pulmonary intralobar sequestration in a patient with cystic fibrosis. Hum Pathol (1997) 1.38
Weight and menstrual function in patients with eating disorders and cystic fibrosis. Pediatrics (1990) 1.37
Symptomatic hepatic disease in cystic fibrosis: incidence, course, and outcome of portal systemic hunting. Gastroenterology (1976) 1.32
Clinical pharmacokinetics in infants and children. A reappraisal. Clin Pharmacokinet (1989) 1.30
A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry (2000) 1.30
Cellular immunity to bacteria: impairment of in vitro lymphocyte responses to Pseudomonas aeruginosa in cystic fibrosis patients. Infect Immun (1977) 1.29
Nontuberculous mycobacteria in cystic fibrosis. An autopsy study. Am J Respir Crit Care Med (1996) 1.29
Caenorhabditis elegans embryos contain only one major species of Ro RNP. RNA (1995) 1.28
A misfolded form of 5S rRNA is complexed with the Ro and La autoantigens. RNA (1996) 1.27
Determination of imipenem and cilastatin in serum by high-pressure liquid chromatography. Antimicrob Agents Chemother (1984) 1.27
Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence. Pediatr Pulmonol (1998) 1.26
Transcriptional activation of the p21(WAF1,CIP1,SDI1) gene by interleukin-6 type cytokines. A prerequisite for their pro-differentiating and anti-apoptotic effects on human osteoblastic cells. J Biol Chem (1998) 1.26
Immediate action needed to improve labeling of prescription drugs for pediatric patients. Ann Pharmacother (1997) 1.25
Exercise conditioning and cardiopulmonary fitness in cystic fibrosis. The effects of a three-month supervised running program. Chest (1981) 1.25
The Ro ribonucleoprotein particle: induction of autoantibodies and the detection of Ro RNAs among species. Clin Immunol Immunopathol (1989) 1.25
Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part I). Clin Pharmacokinet (1988) 1.22
Role of cell-generated hydrogen peroxide in granulocyte-mediated killing of schistosomula of Schistosoma mansoni in vitro. J Clin Invest (1981) 1.22
Bronchial artery embolization to control hemoptysis in cystic fibrosis. Radiology (1990) 1.20
Molecular analysis of a major antigenic region of the 240-kD protein of Mi-2 autoantigen. J Clin Invest (1995) 1.18
An evaluation of optimal sampling strategy and adaptive study design. Clin Pharmacol Ther (1988) 1.18
Evaluation of predictors of weaning from mechanical ventilation in pediatric patients. Pediatr Pulmonol (1997) 1.18
Considerations in the rational design and conduct of phase I/II pediatric clinical trials: avoiding the problems and pitfalls. Clin Pharmacol Ther (2007) 1.18
Treatment and prognosis of massive hemoptysis in cystic fibrosis. Am Rev Respir Dis (1978) 1.15
Open thoracotomy for pneumothorax in cystic fibrosis. Am Rev Respir Dis (1975) 1.15
Defective cellular immunity to gram-negative bacteria in cystic fibrosis patients. Infect Immun (1979) 1.14
Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response. J Antimicrob Chemother (1983) 1.12
Y3 is the most conserved small RNA component of Ro ribonucleoprotein complexes in vertebrate species. Gene (1995) 1.12
Propofol bashing: the time to stop is now! Crit Care Med (1996) 1.12
Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr (1990) 1.11
Determination of ceftazidime in biological fluids by using high-pressure liquid chromatography. Antimicrob Agents Chemother (1983) 1.09
Linkage of DNA markers to cystic fibrosis in 26 families. Am J Hum Genet (1986) 1.09
Course of cystic fibrosis in black patients. J Pediatr (1976) 1.09
Optimal positive end-expiratory pressure therapy in infants and children with acute respiratory failure. Pediatr Res (1988) 1.08
Management of nutritional and infectious complications of postoperative chylothorax in children. J Pediatr Surg (1991) 1.06
Safety of antihistamines in children. Drug Saf (2001) 1.06
Treatment and prognosis of rectal prolapse in cystic fibrosis. Gastroenterology (1982) 1.06
Timing of referral for lung transplantation for cystic fibrosis: overemphasis on FEV1 may adversely affect overall survival. Chest (1999) 1.05
Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children. Antimicrob Agents Chemother (1994) 1.04
Pathophysiologic basis for symptomatic treatment of fever. Pediatrics (1977) 1.04
The pathology of fungal infection and colonization in patients with cystic fibrosis. Hum Pathol (1989) 1.04
Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis. J Pediatr (1984) 1.04
Treatment and prognosis of symptomatic gallbladder disease in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr (1986) 1.03
Purine nucleoside metabolism in the erythrocytes of patients with adenosine deaminase deficiency and severe combined immunodeficiency. J Clin Invest (1976) 1.03
Obstructive azoospermia as a diagnostic criterion for the cystic fibrosis syndrome. Lancet (1982) 1.02
Randomized clinical trial of topical mupirocin versus oral erythromycin for impetigo. Antimicrob Agents Chemother (1988) 1.02
Anomalies of the left renal vein: analysis of 433 CT scans. J Comput Assist Tomogr (1982) 1.01
Ketamine-midazolam versus meperidine-midazolam for painful procedures in pediatric oncology patients. J Clin Oncol (1997) 1.01
Optimal sedation of mechanically ventilated pediatric critical care patients. Crit Care Med (1994) 1.00
The spectrum of appendiceal disease in cystic fibrosis. J Pediatr Surg (1990) 1.00
Treatment and prognosis of lobar and segmental atelectasis in cystic fibrosis. Am Rev Respir Dis (1978) 1.00
The clinical pharmacology of vancomycin in seriously ill preterm infants. Pediatr Res (1987) 0.99
Beta adrenergic receptors in lymphocytes and granulocytes from patients with cystic fibrosis. J Clin Invest (1983) 0.98
Cystic fibrosis care-further considerations. Arch Dis Child (1972) 0.98
Longitudinal serum IgG response to Pseudomonas cepacia surface antigens in cystic fibrosis. Pediatr Pulmonol (1991) 0.97
Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow. J Clin Invest (1997) 0.97
Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis. Am J Med (1987) 0.97
Halothane inhibits two components of calcium current in clonal (GH3) pituitary cells. J Neurosci (1991) 0.97
Antigenicity of a recombinant Ro (SS-A) fusion protein. Arthritis Rheum (1990) 0.96
Comparison of the efficacy and safety of ceftriaxone to ampicillin/chloramphenicol in the treatment of childhood meningitis. J Antimicrob Chemother (1984) 0.96